Last reviewed · How we verify
filgrastim and pegylated filgrastim
Filgrastim and pegylated filgrastim stimulate the production of white blood cells, specifically neutrophils, to help the body fight infection.
Filgrastim and pegylated filgrastim stimulate the production of white blood cells, specifically neutrophils, to help the body fight infection. Used for Reduced febrile neutropenia in patients receiving myelosuppressive chemotherapy, Reduced infection risk in patients undergoing myeloablative chemotherapy or radiation.
At a glance
| Generic name | filgrastim and pegylated filgrastim |
|---|---|
| Sponsor | Chinese Academy of Medical Sciences |
| Drug class | G-CSF agonist |
| Target | G-CSFR |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Filgrastim and pegylated filgrastim work by binding to and activating the granulocyte colony-stimulating factor receptor (G-CSFR), which triggers a signaling cascade that leads to the release of neutrophils from the bone marrow into the bloodstream. Pegylated filgrastim has a longer half-life than filgrastim due to the addition of polyethylene glycol (PEG) chains, allowing for less frequent dosing.
Approved indications
- Reduced febrile neutropenia in patients receiving myelosuppressive chemotherapy
- Reduced infection risk in patients undergoing myeloablative chemotherapy or radiation
Common side effects
- Bone pain
- Headache
- Nausea
- Injection site reaction
- Fatigue
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: